Drug Profile
Research programme: CCR5/CXCR4 antagonists - Queen Mary College/King's College London
Alternative Names: CCR5/CXCR4 antagonists research programme - Queen Mary College/King's College LondonLatest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator Nonindustrial sources
- Developer BTG; Nonindustrial sources
- Class
- Mechanism of Action CCR5 receptor antagonists; CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 30 Jul 1999 Available for licensing (http://www.btg.co.uk)
- 30 Jul 1999 Rights acquired by British Technology Group